Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 16.04 as of 2026-10-06T19:55:31.814Z.
Consensus retrieved: 2026-10-06T08:28:09.639Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:55:31.814Z.
Quote observation: 2026-10-06T19:55:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b7b0029ff709538cee8207ca3143d714f1ded7598a0d3eb5e11b70f8c659e626
Forward PE Ratio (16.04) = Dated Quote Price ($113.04) / Consensus Forward EPS ($7.05)
FORWARD PE RATIO
16.04
SECTOR MEDIAN · HEALTHCARE
19.83
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
-19.11%
vs the sector median at left
Addus HomeCare Corporation
Market Cap
$2.11B
Forward PE Ratio
16.04
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Addus HomeCare Corporation (ADUS) | $2.11B | 16.04 |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | N/A |
| Vera Therapeutics, Inc. (VERA)vs › | $2.10B | N/A |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | N/A |
| Alvotech (ALVO)vs › | $2.08B | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | N/A |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.16B | N/A |
| Pharvaris N.V. (PHVS)vs › | $2.17B | N/A |
| Vericel Corporation (VCEL)vs › | $2.05B | 74.76 |
Trailing P/E
19.8
reported TTM EPS
Forward P/E
16.0
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $7.05 implies +23.7% EPS growth vs the reported trailing $5.70.
At the dated quote price of $113.04, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $7.05 | $6.96 – $7.14 | 9 | 16.0x |
| 2027-12-31 | $7.51 | $7.41 – $7.66 | 9 | 15.1x |
| 2028-12-31 | $8.00 | $7.32 – $8.99 | 4 | 14.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
